DR JOHN LANGLANDS – STRATEGIC ADVISOR
Dr. John Langlands has over 30 years of experience directed towards the development of new medicines. He has been involved in drug development programs related to inflammatory diseases, psychiatric disorders, and oncology, involving both traditional development pathways, and those with orphan disease designations, accelerated approval, and conditions amenable to early access provision (EAP) to patients. John is passionate about working to bring medicines to patients with difficult-to-treat conditions and limited treatment options, in a timely manner through FDA-mandated early access programs. He obtained his Ph.D. from the University of Strathclyde in Glasgow, and has been involved in preclinical and clinical translational medicine approaches to drug development, and ways to bring new treatments to patients as fast as possible. John has held senior corporate roles in preclinical and clinical programs and was program director for postgraduate programs in Drug Development & Pharmaceutical Medicine at UNSW in Sydney (AU). Since 2008, he has worked as an independent consultant to several biopharmaceutical companies. He was a founding and past Chair of Vancouver Pharmaceutical and BioScience Society (PBSS).